SELLAS Granted FDA Rare Paediatric Disease Designation for Acute Myeloid Leukemia

SELLAS Granted FDA Rare Paediatric Disease Designation for Acute Myeloid Leukemia

By, Admin 17 October 2024

Overview

SELLAS Life Sciences Group has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA). 

Paediatric Acute Myeloid leukaemia

  • Paediatric acute myeloid leukaemia (AML) is a rare but aggressive cancer affecting children's blood and bone marrow. 
  • It disrupts normal blood cell production, leading to uncontrolled growth of abnormal myeloid cells. 
  • Treatment typically involves chemotherapy, but outcomes remain poor, particularly for those who relapse or don’t respond to therapy.

GPS targets Wilms Tumor-1 (WT1) and is being developed for the treatment of pediatric acute myeloid leukemia (AML).

Need for Novel Oportunity

The designation highlights the need for new treatment options for pediatric AML, which continues to have a poor prognosis, especially in cases of relapse or resistance to current therapies. 

Relapse & Prevalence

  • Around 50% of children with AML experience relapse, and for those whose remission lasts less than 12 months, the five-year survival rate is only 15.7%. 
  • For patients who do not achieve complete remission after the first course of chemotherapy, the survival rate drops to 0%. 

Current Treatment Options

Currently, bone marrow transplants remain the only curative option for relapsed or refractory cases, with chemotherapy primarily used to induce remission before transplantation.

Previous Trial Outcomes

  • In earlier trials with adult AML patients, GPS demonstrated a median overall survival (OS) of 67.6 months and an ability to stimulate immune responses, specifically through T-lymphocytes. 
  • Younger patients, in particular, showed better outcomes, with many remaining leukemia-free for over five years. The safety profile of GPS was favourable across all age groups.

The Granted Approvals

  • The RPDD granted by the FDA is aimed at rare and serious diseases affecting fewer than 200,000 individuals under the age of 18 in the United States. 
  • Should GPS eventually receive FDA approval for pediatric AML, SELLAS could be eligible for a Priority Review Voucher (PRV), which can expedite the review of a future drug application.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!